{
    "clinical_study": {
        "@rank": "100988", 
        "arm_group": [
            {
                "arm_group_label": "Cephalexin (Reference)", 
                "arm_group_type": "Experimental", 
                "description": "Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods"
            }, 
            {
                "arm_group_label": "Cephalexin (Test)", 
                "arm_group_type": "Active Comparator", 
                "description": "Cephalexin manufactured in Brasil by Antibioticos do Brasil Ltda administered once orally in one of two study periods"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare two different preparations of an antibiotic called\n      cephalexin to determine if they are essentially the same. The study has two periods.\n      Participants will receive one preparation of cephalexin in each period. At least 7 hours\n      will pass between the study periods. The study is expected to last about 2 days for each\n      participant, not including screening or follow-up."
        }, 
        "brief_title": "A Study of Cephalexin Suspension in Healthy Participants", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participation will be voluntary.\n\n          -  The body mass index of participants should be between 18-27.\n\n          -  Participants should have a good health status.\n\n          -  Limits of variation allowed within normal values at screening will be: blood pressure\n             (seated) up to 139 millimeters of mercury (mm Hg), for systolic, and up to 89 mm Hg\n             for diastolic; heart rate between 60 and 100 beats per minute, and respiratory rate\n             between 14 and 20 breaths per minute.\n\n          -  Hepatitis B and C and human immunodeficiency virus (HIV) negative.\n\n          -  Drug abuse or alcohol detection test approximately 12 hours before administering the\n             study medication.\n\n          -  Serum pregnancy test (beta human chorionic gonadotropin) at screening and urine\n             pregnancy test approximately 12 hours before administering the study medication.\n\n        Exclusion Criteria:\n\n          -  Participants with any clinically significant abnormality in their vital sign\n             constants recorded at screening.\n\n          -  Sponsor\u00b4s and/or site employees.\n\n          -  Abnormal 12 lead electrocardiogram (ECG) that in the opinion of the investigator\n             places the participant at an unacceptable risk for study participation, Bazett\n             corrected QR interval (QTcB) > 470 millisecond (msec) for women and > 450 msec for\n             men.\n\n          -  Participants with history of cardiovascular, renal, hepatic, muscular, metabolic,\n             gastrointestinal diseases, including constipation, neurological, endocrine,\n             hematopoietic diseases, or any type of anemia, asthma, mental disease, or other\n             organic abnormalities.\n\n          -  Participants with a creatinine clearance < 80 mL/min based on the Cockcroft-Gault\n             equation.\n\n          -  Participants requiring any medication during the study, apart from the medication\n             which is being studied.\n\n          -  Participants with history of dyspepsia, gastritis, esophagitis, duodenal or gastric\n             ulcer.\n\n          -  Participants who have been exposed to medications known as hepatic enzyme inducers or\n             inhibitors or who have been taking potentially toxic medications within the 30 days\n             prior.\n\n          -  Participants who have received any medication, including vitamins (with or without\n             medical prescription) or herbal-based remedies 30 days (or 7 half-lives) prior to the\n             beginning of the study.\n\n          -  Participants who have been hospitalized for any condition within six months to the\n             beginning of the study.\n\n          -  Participants who have received investigational drugs within the 60 days prior to the\n             study.\n\n          -  Participants allergic to any medication, food, or substance.\n\n          -  Participants who require therapy with nephrotoxic drugs.\n\n          -  Participants who have donated 450 mL of blood or more within the 60 days prior to the\n             beginning of the study.\n\n          -  Participants with history of drug and alcohol abuse.\n\n          -  Participants with special diet requirement for any cause.\n\n          -  Participants with positive to pregnancy test or are breastfeeding.\n\n          -  Participants on hormonal treatment by any route.\n\n          -  Participants who have not been recorded in the page of the Comisi\u00f3n Federal para la\n             Protecci\u00f3n contra Riesgos Sanitarios (COFEPRIS)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02123459", 
            "org_study_id": "15314", 
            "secondary_id": "A3Q-ME-AFBQ"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cephalexin (Reference)", 
                "Cephalexin (Test)"
            ], 
            "description": "Administered orally", 
            "intervention_name": "Cephalexin", 
            "intervention_type": "Drug", 
            "other_name": "Keflex\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": "Cephalexin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 16, 2014", 
        "location": {
            "contact": {
                "last_name": "Eli Lilly"
            }, 
            "facility": {
                "address": {
                    "city": "Mexico City", 
                    "country": "Mexico", 
                    "zip": "14610"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Two-period, Two-treatment, Two-sequence, Crossover Study to Evaluate the Bioequivalence of Single Doses of Two Oral Preparations in Suspension With 250 mg/5 ml of Cephalexin (Keflex\u00ae Liquido Made in Mexico by Eli Lilly y Compa\u00f1\u00eda de M\u00e9xico, S.A. de C.V. vs. Keflex\u00ae Liquido Made by Antibioticos do Brasil Ltda for Eli Lilly y Compa\u00f1\u00eda de M\u00e9xico, S.A. de C.V.) in Fasting Healthy Volunteers", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Mexico: Federal Commission for Protection Against Health Risks", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-\u221e)] of Cephalexin Following a Single Dose", 
            "safety_issue": "No", 
            "time_frame": "Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, and 7.0 hours in each period"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02123459"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: Maximum Concentration (Cmax) of Cephalexin", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, and 7.0 hours in each period"
            }, 
            {
                "measure": "Pharmacokinetics: Time to Reach Maximum Observed Concentration (Tmax) of Cephalexin Following a Single Dose Maximum", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, and 7.0 hours in each period"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "collaborator": {
                "agency": "Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V.", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}